With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
These bulk orders will contribute to the topline of the company as well as help in improving EBITDA of the company
Floods had forced the plans in Mahad to shut down
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The initial consideration for the transaction is US$ 12 million
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy
Subscribe To Our Newsletter & Stay Updated
